Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Prazepam
- Accession Number
- DB01588
- Type
- Small Molecule
- Groups
- Approved, Illicit
- Description
Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.
- Structure
Structure for DB01588 (Prazepam)
- Synonyms
- Prazepamum
- External IDs
- W 4020
- International/Other Brands
- Centrax / Demetrin / Lysanxia / Sedapran / Trepidan
- Categories
- UNII
- Q30VCC064M
- CAS number
- 2955-38-6
- Weight
- Average: 324.804
Monoisotopic: 324.102940883 - Chemical Formula
- C19H17ClN2O
- InChI Key
- MWQCHHACWWAQLJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
- IUPAC Name
- 7-chloro-1-(cyclopropylmethyl)-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
- SMILES
- ClC1=CC2=C(C=C1)N(CC1CC1)C(=O)CN=C2C1=CC=CC=C1
Pharmacology
- Indication
For the treatment of anxiety disorders.
- Pharmacodynamics
Prazepam is a benzodiazepine derivative drug. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Benzodiazepines may be habit-forming (causing mental or physical dependence), especially when taken for a long time or in high doses.
- Mechanism of action
Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic.
- Route of elimination
- Not Available
- Half life
36-200 hours
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Prazepam is combined with 7-Nitroindazole. Experimental Acepromazine The risk or severity of adverse effects can be increased when Prazepam is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Prazepam is combined with Aceprometazine. Approved Acetyl sulfisoxazole The metabolism of Prazepam can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Adipiplon The risk or severity of adverse effects can be increased when Prazepam is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Prazepam is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Prazepam is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Prazepam is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Prazepam. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Prazepam is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Prazepam. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Prazepam is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Prazepam. Approved, Illicit, Investigational Ambroxol acefyllinate The therapeutic efficacy of Prazepam can be decreased when used in combination with Ambroxol acefyllinate. Experimental, Investigational Aminophylline The therapeutic efficacy of Prazepam can be decreased when used in combination with Aminophylline. Approved Amiodarone The metabolism of Prazepam can be decreased when combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Prazepam is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Prazepam. Approved Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Prazepam. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Prazepam. Approved Amperozide The risk or severity of adverse effects can be increased when Prazepam is combined with Amperozide. Experimental Apalutamide The serum concentration of Prazepam can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Prazepam can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Prazepam is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Asenapine is combined with Prazepam. Approved Atazanavir The metabolism of Prazepam can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Prazepam can be decreased when combined with Atomoxetine. Approved Azaperone The risk or severity of adverse effects can be increased when Prazepam is combined with Azaperone. Investigational, Vet Approved Azelastine Prazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Prazepam. Approved Barbital The risk or severity of adverse effects can be increased when Barbital is combined with Prazepam. Illicit Benperidol The risk or severity of adverse effects can be increased when Prazepam is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Benzocaine is combined with Prazepam. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Prazepam is combined with Benzyl alcohol. Approved Boceprevir The metabolism of Prazepam can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Prazepam can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Prazepam can be decreased when it is combined with Bosentan. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Prazepam. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Prazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Prazepam is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Prazepam is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Prazepam. Approved Brotizolam The risk or severity of adverse effects can be increased when Prazepam is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazepam. Approved, Investigational Buprenorphine Prazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Prazepam. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Prazepam. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Prazepam is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Prazepam. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Prazepam is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Butethal is combined with Prazepam. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Prazepam. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Prazepam is combined with Canertinib. Investigational Carbamazepine The metabolism of Prazepam can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Prazepam. Approved Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Prazepam. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Prazepam. Approved Ceritinib The serum concentration of Prazepam can be increased when it is combined with Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Prazepam. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Prazepam. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Prazepam. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Chlormezanone is combined with Prazepam. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Prazepam. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prazepam. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazepam. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Prazepam. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Prazepam. Approved Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Prazepam. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram. Approved Clarithromycin The metabolism of Prazepam can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Prazepam can be decreased when combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Prazepam. Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Prazepam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Prazepam is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Prazepam. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Prazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Clonidine is combined with Prazepam. Approved Clopenthixol The risk or severity of adverse effects can be increased when Prazepam is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Prazepam. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Prazepam is combined with Clothiapine. Experimental Clotrimazole The metabolism of Prazepam can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Prazepam is combined with Clozapine. Approved Cobicistat The metabolism of Prazepam can be decreased when combined with Cobicistat. Approved Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Prazepam. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Prazepam. Approved, Illicit Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Prazepam. Approved, Investigational Crizotinib The metabolism of Prazepam can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Prazepam can be decreased when combined with Curcumin. Approved, Investigational Cyclizine The risk or severity of adverse effects can be increased when Cyclizine is combined with Prazepam. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam. Approved Cyclopropane The risk or severity of adverse effects can be increased when Prazepam is combined with Cyclopropane. Experimental Cyclosporine The metabolism of Prazepam can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Prazepam. Approved Dabrafenib The serum concentration of Prazepam can be decreased when it is combined with Dabrafenib. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Prazepam. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dapiprazole is combined with Prazepam. Approved Dapoxetine The risk or severity of adverse effects can be increased when Prazepam is combined with Dapoxetine. Investigational Darunavir The metabolism of Prazepam can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Prazepam can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Prazepam can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Prazepam can be decreased when combined with Delavirdine. Approved Deramciclane The risk or severity of adverse effects can be increased when Prazepam is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Prazepam. Approved Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Prazepam. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Prazepam. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Prazepam is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Prazepam is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Prazepam. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Prazepam. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Prazepam. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prazepam. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Prazepam. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Prazepam. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Prazepam is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Difenoxin is combined with Prazepam. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prazepam. Approved, Illicit Dihydroergotamine The metabolism of Prazepam can be decreased when combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Prazepam. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prazepam. Experimental, Illicit Diltiazem The metabolism of Prazepam can be decreased when combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Prazepam. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prazepam. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prazepam. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Prazepam is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Prazepam is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Prazepam. Approved, Investigational Doxycycline The metabolism of Prazepam can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Prazepam is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved, Illicit Dronedarone The metabolism of Prazepam can be decreased when combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Drotebanol is combined with Prazepam. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Prazepam is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam. Approved Dyphylline The therapeutic efficacy of Prazepam can be decreased when used in combination with Dyphylline. Approved Ecgonine The risk or severity of adverse effects can be increased when Ecgonine is combined with Prazepam. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Prazepam is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Prazepam. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Prazepam is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Enflurane is combined with Prazepam. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Prazepam. Approved, Investigational Enzalutamide The serum concentration of Prazepam can be decreased when it is combined with Enzalutamide. Approved Erythromycin The metabolism of Prazepam can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Prazepam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Prazepam. Approved, Investigational Ethanol Prazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Prazepam. Approved Ethotoin The risk or severity of adverse effects can be increased when Ethotoin is combined with Prazepam. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Prazepam. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Prazepam. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Prazepam is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Prazepam is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Prazepam is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam. Approved Etoperidone The risk or severity of adverse effects can be increased when Prazepam is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Prazepam. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Ezogabine is combined with Prazepam. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Prazepam. Approved Fencamfamine The risk or severity of adverse effects can be increased when Fencamfamine is combined with Prazepam. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Prazepam. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Fexofenadine is combined with Prazepam. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Flibanserin is combined with Prazepam. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Prazepam is combined with Fluanisone. Experimental Fluconazole The metabolism of Prazepam can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Fludiazepam is combined with Prazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Prazepam. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Prazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Prazepam is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Flupentixol is combined with Prazepam. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Prazepam. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Prazepam. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Prazepam is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Prazepam. Approved Fluvoxamine The metabolism of Prazepam can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Prazepam can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Prazepam can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Prazepam. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Prazepam is combined with Fospropofol. Approved, Illicit, Investigational Fusidic Acid The serum concentration of Prazepam can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Prazepam. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Prazepam. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Prazepam. Approved, Illicit, Investigational Gepirone The risk or severity of adverse effects can be increased when Prazepam is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Glutethimide is combined with Prazepam. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Prazepam. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Halazepam is combined with Prazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Haloperidol is combined with Prazepam. Approved Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Prazepam. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Prazepam. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Hexobarbital is combined with Prazepam. Approved Hyaluronidase The therapeutic efficacy of Prazepam can be decreased when used in combination with Hyaluronidase. Approved, Investigational Hydrocodone Prazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved Idelalisib The metabolism of Prazepam can be decreased when combined with Idelalisib. Approved Iloperidone The risk or severity of adverse effects can be increased when Iloperidone is combined with Prazepam. Approved Imatinib The metabolism of Prazepam can be decreased when combined with Imatinib. Approved Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Prazepam. Approved Indalpine The risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine. Investigational, Withdrawn Indinavir The metabolism of Prazepam can be decreased when combined with Indinavir. Approved Indiplon The risk or severity of adverse effects can be increased when Prazepam is combined with Indiplon. Investigational Isavuconazole The serum concentration of Prazepam can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Prazepam can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid The therapeutic efficacy of Prazepam can be increased when used in combination with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Prazepam. Approved, Vet Approved Isradipine The metabolism of Prazepam can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Prazepam can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Prazepam can be increased when it is combined with Ivacaftor. Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Prazepam. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Ketazolam is combined with Prazepam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Prazepam is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Prazepam can be decreased when combined with Ketoconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Prazepam. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Prazepam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Prazepam. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Prazepam is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Prazepam. Approved Levodopa The risk or severity of adverse effects can be increased when Levodopa is combined with Prazepam. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Prazepam. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Prazepam. Approved Lidocaine The risk or severity of adverse effects can be increased when Lidocaine is combined with Prazepam. Approved, Vet Approved Lithium cation The risk or severity of adverse effects can be increased when Lithium is combined with Prazepam. Experimental Lofentanil The risk or severity of adverse effects can be increased when Prazepam is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Prazepam can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir The metabolism of Prazepam can be decreased when combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Prazepam is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Loratadine is combined with Prazepam. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Prazepam. Approved Lormetazepam The risk or severity of adverse effects can be increased when Prazepam is combined with Lormetazepam. Approved Lorpiprazole The serum concentration of Prazepam can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Prazepam can be decreased when combined with Lovastatin. Approved, Investigational Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Prazepam. Approved Luliconazole The serum concentration of Prazepam can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Prazepam can be increased when combined with Lumacaftor. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Prazepam. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Prazepam can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Prazepam. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Prazepam is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Prazepam. Approved Medazepam The risk or severity of adverse effects can be increased when Prazepam is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Prazepam is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Melatonin is combined with Prazepam. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Prazepam is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Mepivacaine is combined with Prazepam. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Prazepam is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Mesoridazine is combined with Prazepam. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Prazepam. Approved Methadone Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Prazepam. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Prazepam is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Prazepam is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Prazepam. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Prazepam. Approved Methotrimeprazine Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Prazepam. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Prazepam. Approved Methylecgonine The risk or severity of adverse effects can be increased when Prazepam is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Prazepam. Approved Metyrosine Prazepam may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam. Approved, Illicit Mifepristone The serum concentration of Prazepam can be increased when it is combined with Mifepristone. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Prazepam is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved, Investigational Mirtazapine Prazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mitotane The serum concentration of Prazepam can be decreased when it is combined with Mitotane. Approved Molindone The risk or severity of adverse effects can be increased when Prazepam is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Prazepam. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Prazepam. Approved Nefazodone The metabolism of Prazepam can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Prazepam can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Prazepam can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Prazepam can be increased when combined with Nevirapine. Approved Nilotinib The metabolism of Prazepam can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Prazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Prazepam. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Prazepam is combined with Nordazepam. Approved Norflurane The risk or severity of adverse effects can be increased when Prazepam is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Prazepam is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Prazepam. Approved Olanzapine The risk or severity of adverse effects can be increased when Prazepam is combined with Olanzapine. Approved, Investigational Olaparib The metabolism of Prazepam can be decreased when combined with Olaparib. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Prazepam. Approved Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Prazepam. Approved Opium The risk or severity of adverse effects can be increased when Prazepam is combined with Opium. Approved, Illicit Orphenadrine Prazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Prazepam is combined with Osanetant. Investigational Osimertinib The serum concentration of Prazepam can be increased when it is combined with Osimertinib. Approved Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Prazepam. Approved Oxprenolol The risk or severity of adverse effects can be increased when Oxprenolol is combined with Prazepam. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Prazepam. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Prazepam. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Prazepam. Approved, Investigational, Vet Approved Palbociclib The serum concentration of Prazepam can be increased when it is combined with Palbociclib. Approved, Investigational Paliperidone The risk or severity of adverse effects can be increased when Paliperidone is combined with Prazepam. Approved Paraldehyde Prazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Prazepam is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam. Approved, Vet Approved Pentobarbital The metabolism of Prazepam can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved Perazine The risk or severity of adverse effects can be increased when Prazepam is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Prazepam is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Prazepam. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Prazepam. Approved Phenazocine The risk or severity of adverse effects can be increased when Prazepam is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Prazepam is combined with Phenibut. Experimental Phenobarbital The metabolism of Prazepam can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Prazepam is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Prazepam is combined with Phenoxyethanol. Approved Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Prazepam. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Pimozide is combined with Prazepam. Approved Pipamperone The risk or severity of adverse effects can be increased when Prazepam is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Pipotiazine is combined with Prazepam. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Prazepam is combined with Piritramide. Approved, Investigational Pitolisant The serum concentration of Prazepam can be decreased when it is combined with Pitolisant. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Pizotifen is combined with Prazepam. Approved Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Prazepam. Approved Posaconazole The metabolism of Prazepam can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole Prazepam may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Prazepam is combined with Pramocaine. Approved Pregabalin The therapeutic efficacy of Prazepam can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Prilocaine is combined with Prazepam. Approved Primidone The metabolism of Prazepam can be increased when combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Prazepam. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prazepam. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Prazepam. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Prazepam. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Prazepam is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Proparacaine is combined with Prazepam. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Prazepam. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Prazepam is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Prazepam. Approved Proxibarbal The risk or severity of adverse effects can be increased when Prazepam is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Prazepam is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Prazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Quetiapine is combined with Prazepam. Approved Quinisocaine The risk or severity of adverse effects can be increased when Prazepam is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Prazepam is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Prazepam. Approved, Investigational Ranolazine The metabolism of Prazepam can be decreased when combined with Ranolazine. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Prazepam. Approved Remoxipride The risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Prazepam. Approved, Investigational Rifabutin The metabolism of Prazepam can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Prazepam can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Prazepam can be increased when combined with Rifapentine. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Prazepam. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Prazepam is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Prazepam is combined with Romifidine. Vet Approved Ropinirole Prazepam may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazepam. Approved Rotigotine Prazepam may increase the sedative activities of Rotigotine. Approved Rucaparib The metabolism of Prazepam can be decreased when combined with Rucaparib. Approved, Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Prazepam. Approved Saquinavir The metabolism of Prazepam can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Prazepam can be decreased when used in combination with Sarilumab. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Prazepam. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Prazepam. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Prazepam is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Prazepam is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Prazepam. Approved, Vet Approved Sildenafil The metabolism of Prazepam can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Prazepam can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Prazepam can be increased when it is combined with Simeprevir. Approved Sodium oxybate Prazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. Approved St. John's Wort The serum concentration of Prazepam can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Prazepam can be increased when it is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam. Approved, Investigational Sulfisoxazole The metabolism of Prazepam can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Prazepam. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Prazepam is combined with Sultopride. Experimental Suvorexant Prazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Prazepam is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. Approved Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Prazepam. Approved, Investigational Teduglutide The serum concentration of Prazepam can be increased when it is combined with Teduglutide. Approved Telaprevir The metabolism of Prazepam can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Prazepam can be decreased when combined with Telithromycin. Approved Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Prazepam. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prazepam. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Prazepam is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Prazepam is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Prazepam is combined with Tetrodotoxin. Investigational Thalidomide Prazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Theophylline The therapeutic efficacy of Prazepam can be decreased when used in combination with Theophylline. Approved Thiamylal The risk or severity of adverse effects can be increased when Thiamylal is combined with Prazepam. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Prazepam. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Prazepam. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Prazepam. Approved Tiagabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Prazepam. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Prazepam is combined with Tiapride. Approved, Investigational Ticlopidine The metabolism of Prazepam can be decreased when combined with Ticlopidine. Approved Tiletamine The risk or severity of adverse effects can be increased when Prazepam is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Prazepam is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Prazepam. Approved, Investigational Tocilizumab The serum concentration of Prazepam can be decreased when it is combined with Tocilizumab. Approved Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Prazepam. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Prazepam. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Prazepam. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Trazodone is combined with Prazepam. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Prazepam. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Prazepam is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Prazepam is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prazepam. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Prazepam is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Prazepam. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Trimipramine is combined with Prazepam. Approved Triprolidine The risk or severity of adverse effects can be increased when Triprolidine is combined with Prazepam. Approved Valproic Acid The risk or severity of adverse effects can be increased when Valproic Acid is combined with Prazepam. Approved, Investigational Vemurafenib The serum concentration of Prazepam can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Prazepam can be decreased when combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Prazepam is combined with Veralipride. Experimental Verapamil The metabolism of Prazepam can be decreased when combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Prazepam. Approved Vinyl ether The risk or severity of adverse effects can be increased when Prazepam is combined with Vinyl ether. Experimental Voriconazole The metabolism of Prazepam can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Prazepam is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Prazepam is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Prazepam is combined with Xylazine. Vet Approved Yohimbine The therapeutic efficacy of Prazepam can be decreased when used in combination with Yohimbine. Approved, Investigational, Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Prazepam. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Prazepam. Approved Zimelidine The risk or severity of adverse effects can be increased when Prazepam is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Prazepam can be decreased when combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Prazepam is combined with Zolazepam. Vet Approved Zolpidem Prazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Prazepam. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Prazepam. Approved Zotepine The risk or severity of adverse effects can be increased when Prazepam is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Prazepam. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Avoid excessive quantities of coffee or tea (Caffeine).
- Avoid taking with grapefruit juice.
- Take with food.
References
- General References
- Not Available
- External Links
- ATC Codes
- N05BA11 — Prazepam
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Physicians Total Care Inc.
- Dosage forms
- Not Available
- Prices
Unit description Cost Unit Doral 15 mg tablet 3.41USD tablet Doral 7.5 mg tablet 3.37USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 145-146 °C PhysProp logP 3.73 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.00399 mg/mL ALOGPS logP 3.68 ALOGPS logP 3.86 ChemAxon logS -4.9 ALOGPS pKa (Strongest Basic) 3.06 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 32.67 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 91.75 m3·mol-1 ChemAxon Polarizability 34.77 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9821 Blood Brain Barrier + 0.9934 Caco-2 permeable + 0.6922 P-glycoprotein substrate Substrate 0.6631 P-glycoprotein inhibitor I Inhibitor 0.7452 P-glycoprotein inhibitor II Inhibitor 0.6438 Renal organic cation transporter Inhibitor 0.6625 CYP450 2C9 substrate Non-substrate 0.7317 CYP450 2D6 substrate Non-substrate 0.8332 CYP450 3A4 substrate Substrate 0.7471 CYP450 1A2 substrate Inhibitor 0.861 CYP450 2C9 inhibitor Inhibitor 0.5153 CYP450 2D6 inhibitor Non-inhibitor 0.7477 CYP450 2C19 inhibitor Inhibitor 0.7793 CYP450 3A4 inhibitor Inhibitor 0.6455 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7974 Ames test Non AMES toxic 0.8623 Carcinogenicity Non-carcinogens 0.8138 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 1.8779 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9819 hERG inhibition (predictor II) Non-inhibitor 0.5471
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Mass Spectrum (Electron Ionization) MS splash10-00r5-3391000000-0113e86cca51d223d412 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzodiazepines
- Sub Class
- 1,4-benzodiazepines
- Direct Parent
- 1,4-benzodiazepines
- Alternative Parents
- Alpha amino acids and derivatives / Benzene and substituted derivatives / Aryl chlorides / Tertiary carboxylic acid amides / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organochlorides show 3 more
- Substituents
- 1,4-benzodiazepine / Alpha-amino acid or derivatives / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Tertiary carboxylic acid amide / Carboxamide group / Ketimine / Lactam show 16 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- benzodiazepine (CHEBI:8362)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRA1
- Uniprot ID
- P14867
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-1
- Molecular Weight
- 51801.395 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Amin J, Brooks-Kayal A, Weiss DS: Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of gamma-aminobutyric acidA receptors. Mol Pharmacol. 1997 May;51(5):833-41. [PubMed:9145922]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA2
- Uniprot ID
- P47869
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-2
- Molecular Weight
- 51325.85 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA3
- Uniprot ID
- P34903
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-3
- Molecular Weight
- 55164.055 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Transporter activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRA5
- Uniprot ID
- P31644
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit alpha-5
- Molecular Weight
- 52145.645 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRG1
- Uniprot ID
- Q8N1C3
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-1
- Molecular Weight
- 53594.49 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRG2
- Uniprot ID
- P18507
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-2
- Molecular Weight
- 54161.78 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRG3
- Uniprot ID
- Q99928
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit gamma-3
- Molecular Weight
- 54288.16 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB1
- Uniprot ID
- P18505
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-1
- Molecular Weight
- 54234.085 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB2
- Uniprot ID
- P47870
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-2
- Molecular Weight
- 59149.895 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-gated chloride ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
- Gene Name
- GABRB3
- Uniprot ID
- P28472
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit beta-3
- Molecular Weight
- 54115.04 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRD
- Uniprot ID
- O14764
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit delta
- Molecular Weight
- 50707.835 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRE
- Uniprot ID
- P78334
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit epsilon
- Molecular Weight
- 57971.175 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
- Gene Name
- GABRP
- Uniprot ID
- O00591
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit pi
- Molecular Weight
- 50639.735 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
- Gene Name
- GABRR1
- Uniprot ID
- P24046
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-1
- Molecular Weight
- 55882.91 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
- Gene Name
- GABRR2
- Uniprot ID
- P28476
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-2
- Molecular Weight
- 54150.41 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Gaba-a receptor activity
- Specific Function
- GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
- Gene Name
- GABRR3
- Uniprot ID
- A8MPY1
- Uniprot Name
- Gamma-aminobutyric acid receptor subunit rho-3
- Molecular Weight
- 54271.1 Da
References
- Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49. [PubMed:7773620]
- Kind
- Protein group
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Positive allosteric modulator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Components:
References
- ChEMBL Compound Report Card [Link]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on August 29, 2007 09:29 / Updated on July 02, 2018 17:36